ASTRAZENECA has announced the Pharmaceutical Benefits Scheme listing of its Fasenra (benralizumab) for patients with severe eosiniphilic asthma who meet specific criteria.
Fasenra is a monoclonal antibody that works with the body's immune system to specifically target eosinophils, a particular type of white blood cell which are present in half of Australians with uncontrolled severe asthma.
It is administered by a healthcare professional as a subcutaneous injection every eight weeks, following initiation with three four-weekly doses.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 18
